Best Grants for HIV / AIDS in Texas

The Texas Pride Community Foundation (TPCF) offers Community Grants to support historically disadvantaged LGBTQ+ communities in Texas. Grants up to $10,000 are available for non-profits addressing community needs without requiring specific project plans. TPCF prioritizes funding for underserved geographies, people of color, and individuals with disabilities, fostering an inclusive approach to grantmaking. The foundation emphasizes community-driven solutions to systemic injustices, aiming to enhance the safety and well-being of diverse populations.

The Texas HIV Medication Program (THMP) provides medications approved by the Food and Drug Administration (FDA) and insurance assistance for the treatment of HIV and its related complications for low-income Texans. To qualify for medications, potential clients who meet eligibility criteria must complete an application for assistance. Once approved, a client receives medications at an assigned pharmacy in their community.

The Texas Health Impact Grant Cohort, led by the Texas Pride Community Foundation, aims to empower grassroots organizations addressing HIV/AIDS challenges, particularly among Black and Latinx communities. This three-year program, beginning in January 2026, focuses on linking individuals to care and promoting advocacy. By fostering innovative solutions, TPCF seeks to enhance the health and well-being of those affected by HIV across Texas, ensuring equitable access to resources and support.

Bristol Myers Squibb is dedicated to enhancing healthcare and advancing scientific knowledge through its Corporate Giving program. By supporting various organizations, BMS aims to improve health equity and access to essential medicines for underserved populations. Their focus includes charitable donations, medical education, and community support initiatives. This commitment reflects BMS's goal to make a positive impact on patients' lives and foster strong communities where their employees work and live.

The ORACLE 3C initiative focuses on advancing research into chronic conditions, coinfections, and comorbidities related to HIV. It aims to support early-career investigators through innovative approaches that diverge from existing methodologies. Emphasizing pediatric and maternal health, this funding opportunity encourages interdisciplinary research to better understand HIV-specific pathways and develop effective preventive and therapeutic strategies, addressing a significant public health concern.

The upcoming National Institute of Mental Health (NIMH) funding opportunity aims to explore the effects of HIV immunotherapies on central nervous system (CNS) outcomes. It seeks to identify mechanisms, benefits, and risks associated with these therapies, focusing on overcoming CNS-specific barriers. The initiative encourages collaborations to develop strategies for achieving sustained virologic remission and improving neurological outcomes for individuals with HIV, particularly targeting neurotoxicity and neuroinflammation.

The National Institute of Allergy and Infectious Diseases (NIAID) is launching a funding opportunity for Clinical Trials Units (CTUs) as part of its effort to combat HIV/AIDS. This initiative aims to support innovative clinical trials and implementation research to improve prevention and treatment strategies. With a focus on both domestic and international research sites, CTUs will play a crucial role in addressing the HIV epidemic and enhancing participant recruitment and retention. This funding opportunity is authorized under the Public Health Service Act.

The NIAID aims to support four Clinical Trials Networks (CTNs) by funding Statistical and Data Management Centers (SDMCs) to enhance HIV research. These SDMCs will oversee study designs, data collection, and compliance with regulatory standards while ensuring data quality and integration. This initiative is a crucial step toward ending the HIV epidemic, fostering innovative methods, and adhering to NIH data sharing policies. Applications for the SDMCs are now being solicited.

The National Institute of Allergy and Infectious Diseases (NIAID) is launching a funding opportunity for up to four Clinical Trials Network Laboratory Centers (LCs). These LCs will support HIV prevention and treatment strategies by providing necessary laboratory infrastructure and technologies for clinical trials. They will ensure rigorous laboratory testing and oversight, enhance sample integrity, and utilize advanced data management systems to meet evolving demands in HIV research and testing.

The National Institute of Allergy and Infectious Diseases (NIAID) is calling for applications for four Leadership and Operations Centers (LOCs) as part of its HIV/AIDS Clinical Trials Network initiative. These LOCs will guide research on HIV therapeutics, prevention, and treatment strategies across diverse populations. The initiative aims to enhance evidence-based practices and improve health outcomes for individuals affected by HIV, ultimately contributing to the goal of ending the HIV epidemic.

The NIDA Core "Center of Transformative Science" Grant Program aims to enhance research on substance use, addiction, and HIV by fostering collaboration among NIH-funded researchers. Centers are expected to innovate and extend existing research through shared resources and support for new investigators. This initiative encourages interdisciplinary work and aims to transform the scientific landscape by promoting data sharing and collaborative opportunities. Applications should focus on integrating research within a specific thematic framework to maximize impact.

This funding opportunity aims to advance HIV/AIDS research by implementing human new approach methodologies (NAMs) to reduce the reliance on specific pathogen free (SPF) animal models. It emphasizes the integration of NAMs-enabled frameworks for in vitro testing while supporting essential SPF colony resources. The initiative seeks to enhance research rigor and reproducibility through innovative strategies that prioritize human-relevant models, ultimately improving HIV research outcomes and facilitating collaborative development in the field.

The National Institute of Mental Health is inviting research applications for the AIDS Research Center program, which includes Developmental Centers and full Research Centers. This initiative aims to enhance interdisciplinary HIV/AIDS research through collaboration and innovative approaches across various scientific domains. The program emphasizes alignment with national strategies and encourages applications from teams skilled in fostering partnerships with diverse stakeholders. Although applications are currently not being solicited, this notice allows potential applicants time to prepare strong proposals.

The Ryan White HIV/AIDS Program (RWHAP) Integrated HIV/AIDS Planning Resource Allocation Cooperative Agreement aims to enhance the effectiveness of HIV prevention and care planning for RWHAP Parts A and B recipients. Through the provision of training, tools, and technical assistance, this initiative seeks to optimize resource allocation and strengthen the overall system of HIV care and treatment, ultimately improving health outcomes for those affected by HIV.

The AIDS Drug Assistance Program (ADAP) Emergency Relief Funds aim to provide essential funding to states and territories. This initiative focuses on preventing, reducing, or eliminating waiting lists for ADAP services, ensuring timely access to necessary medications and support for individuals living with HIV/AIDS. This program addresses critical funding shortfalls, enhancing the healthcare infrastructure and improving health outcomes in affected communities.

The Ryan White HIV/AIDS Program Part C Capacity Development Program aims to enhance the capabilities of community-based organizations, focusing on improving health outcomes and decreasing HIV transmission. This initiative supports individuals who have not yet accessed regular HIV care, emphasizing innovative care solutions and infrastructure development to address these critical needs.

The HIV Care Grant Program, funded by the US HHS: Health Resources & Services Administration (HRSA), aims to enhance access to high-quality HIV care and treatment for low-income individuals. This initiative supports states and territories in developing comprehensive systems to address the needs of those living with HIV. By providing essential resources, the program seeks to improve health outcomes and ensure that vulnerable populations receive the necessary support and services.

The Ryan White HIV/AIDS Program Part B Supplemental Grant aims to provide essential funding to support HIV care and treatment services across states and territories. This program supplements existing formula-based funding from the RWHAP Part B and ADAP, improving access to necessary resources for those affected by HIV/AIDS. By enhancing support structures, it addresses critical healthcare needs, ensuring better health outcomes for vulnerable populations.

The HIV Care Grant Program aims to enhance access to comprehensive, high-quality HIV care and treatment for low-income individuals in Pacific Island territories. Funded by the US HHS: Health Resources & Services Administration (HRSA), this initiative supports states and territories in developing effective systems of care, ensuring that those affected by HIV receive the necessary treatment and support to improve health outcomes.

This funding opportunity aims to enhance a web-based ordering portal for distributing 1.5 million HIV and STI self-tests to high-burden communities. By optimizing access to these self-tests, the initiative seeks to raise awareness, prevent new infections, and improve the health outcomes of users, thereby contributing to better overall public health and wellbeing.

This project aims to enhance health outcomes for women living with HIV in the South by integrating HIV care with comprehensive women's health services through coordinated Clinic and Community Collaboratives. By funding organizations to implement targeted strategies such as culturally responsive services and learning collaboratives, the initiative seeks to improve access to essential health services, increase the number of women initiating rapid ART, and foster sustainable healthcare models that address the unique needs of this population.

The Ryan White HIV/AIDS Program Part D provides supplemental funding aimed at enhancing the infrastructure and capacity of organizations to deliver high-quality, family-centered HIV care services. This initiative focuses on two key areas: HIV Care Innovation and Infrastructure Development, ensuring improved access to essential services for women, infants, children, and youth affected by HIV.

The Ryan White HIV/AIDS Program Part B AIDS Drug Assistance Program Training and Technical Assistance aims to enhance the capacity of ADAPs. By providing essential tools and expert guidance, the program seeks to improve health outcomes for individuals living with HIV in an evolving healthcare landscape. This initiative is funded by the US HHS through the Health Resources & Services Administration, ensuring support and resources are effectively allocated to meet the needs of vulnerable populations.

Gilead Sciences

At Gilead, we are relentlessly committed to advancing transformative therapies for the most serious diseases, delivering an exponentially positive impact on health.

For more than three decades, we have combined scientific rigor with a deep sense of purpose to improve health outcomes and reimagine care. Our work spans more than 35 countries with a focus on three therapeutic areas: virology, oncology, and inflammation, where unmet medical needs remain greatest.

From individual patients to whole populations, we’re committed to delivering healthier futures for people and communities worldwide.

Our Mission: To discover, develop and deliver innovative therapeutics for people with life-threatening diseases.

HIV Prevention NOVA 2026

Program Description

Gilead Sciences invites research proposals that advance the evidence base for innovative and scalable models of delivery for long-acting (LA) HIV pre-exposure prophylaxis (PrEP) in the United States.

This Topic of Interest (TOI) is focused on care delivery models implemented in non-traditional settings, defined as clinical and non-clinical environments where PrEP services are not routinely provided. Emphasis is placed on approaches that reflect real-life practice and address gaps in current PrEP delivery infrastructure.

Persistent inequities in PrEP uptake in the U.S. suggest that expanding availability within traditional clinical settings alone is unlikely to reach all populations with unmet PrEP need.1,2 Rigorous implementation studies in non-traditional settings where PrEP services are not routinely provided are needed to evaluate whether these models can reduce access barriers and improve equitable reach among individuals who may benefit from PrEP.2,3,4

The goal of this TOI is to generate practical, decision-relevant evidence that informs how LA PrEP can be implemented, scaled, and sustained in real-life U.S. settings.

About Patient Advocate Foundation

Patient Advocate Foundation is the nation’s most comprehensive nonprofit dedicated to helping patients navigate, access, and afford the care they need—while improving the healthcare system for all.

Who we are and our impact

Patient Advocate Foundation provides financial assistance to help patients afford treatment and cost of living needs, personalized case management to navigate complex healthcare and social needs challenges, and a wide array of resources to empower people to take charge of their health. Since our founding in 1996—and joining forces with the PAN Foundation in 2026—we have helped 3.8 million patients navigate and access care, granted over $7 billion in financial assistance, served 350,000 people through personalized case management and elevated the patient’s voice to drive improvements in the healthcare system.

HIV, AIDS, and prevention

Help with healthcare costs for HIV, AIDS, and prevention

This TotalAssist fund helps you pay for out-of-pocket healthcare costs, including medication copays, coinsurance, and deductibles, health insurance premiums, and other expenses.

About the disease

HIV, also known as human immunodeficiency virus or acquired immunodeficiency syndrome, is a virus that attacks the immune system. When left untreated, it can develop into AIDS. HIV is a chronic disease that affects the immune system.

The SCORCH Program: Phase 2 aims to enhance the understanding of single cell biology in the context of HIV and Substance Use Disorder (SUD). Building on previous research, this initiative will explore new single cell approaches to investigate the interactions between SUD and HIV progression at various biological levels. By leveraging advanced techniques, the program seeks to identify candidate mechanisms and potential therapeutic targets, ultimately contributing to innovative solutions for SUDs and HIV-related challenges.

The Elizabeth Taylor AIDS Foundation (ETAF) provides grants focused on HIV/AIDS care, advocacy, and education. Grants are awarded annually based on a review process, emphasizing projects that align with Ms. Taylor’s vision. Eligible organizations must have at least three years of experience in HIV/AIDS programs and can apply only once per year. ETAF prioritizes funding for direct care and prevention initiatives, while restricting support for multi-year proposals and non-HIV specific projects.